Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients

Pharmacotherapy

Volumn 36, Issue 5, 2016, Pages 488-495

  Nguyen, Elaine ^a,b   Egri, Florence ^a   Mearns, Elizabeth S ^b   White, Charles M ^a,b   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

anticoagulation; atrial fibrillation; cost effectiveness; Markov model; stroke

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DRUG COST; DRUG MEGADOSE; HUMAN; INTERNATIONAL NORMALIZED RATIO; NONVALVULAR ATRIAL FIBRILLATION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; UNITED STATES; AGED; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; MALE; MARKOV CHAIN; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; PYRIDINES; QUALITY-ADJUSTED LIFE YEARS; STROKE; THIAZOLES; WARFARIN;

EID: 84970024647     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1746     Document Type: Article

References (36)

1. Giugliano RP, Ruff CT, Braunwald E, et al., Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
2. Daiichi Sankyo Co., LTD. Savaysa [package insert]. Tokyo, Japan; 2015.
3. Gage BF, Waterman AD, Shannon W, et al., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
4. Red Book Online [database online]. Greenwood Village, CO: Truven Health Analytics, Inc. Updated periodically. Accessed July 13, 2015.
5. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC,. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013; 44: 1676-81.
6. Roche Diagnostics and American Medical Association. Medicare reimbursement handbook for healthcare professionals. Publication date 2009. Available from http://www.omnimedicalsupply.com/Roche/Reimbursement%20CoagHandbook%202009.pdf. Accessed January 20, 2015.
7. Jonas DE, Shilliday BB, Laundon WR, Pignone M,. Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making 2010; 30: 206-16.
8. HCUP Databases. Healthcare Cost and Utilization Project (HCUP) [database online]. Rockville, MD: Agency for Healthcare Research and Quality. Available from http://hcupnet.ahrq.gov/. Accessed January 20, 2015.
9. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB,. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-8.
10. Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
11. Gage BF, Cardinalli AB, Owens DK,. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996; 156: 1829-36.
12. O'Brien CL, Gage BF,. Costs and effectiveness of ximelagatron stroke prophylaxis in chronic atrial fibrillation. JAMA 2005; 293: 669-706.
13. Sullivan PW, Ghushchyan V,. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006; 26: 410-20.
14. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A,. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355: 956-62.
15. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
16. van Walraven C, Hart RJ, Singer DE, et al., Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441-8.
17. Ariesen MJ, Claus SP, Rinkel GJ, Algra A,. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003; 34: 2060-5.
18. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM,. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-15.
19. Hylek EM, Singer DE,. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
20. Freeman JV, Zhu RP, Owens DK, et al., Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
21. Krumholz HM, Merrill AR, Schone EM, et al., Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes 2009; 2: 407-13.
22. Dries DL, Exner DV, Gersh BJ, et al., Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: 695-703.
23. Dennis MS, Burn JP, Sandercock PA, et al., Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993; 24: 796-800.
24. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B,. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
25. Gulløv AL, Koefoed BG, Petersen P, et al., Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158: 1513-21.
26. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996; 348: 633-8.
27. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
28. United States Census Bureau. The 2012 Statistical Abstract [internet]. Washington, DC: US Department of Commerce. Available from https://www.census.gov/compendia/statab/cats/births-deaths-marriages-divorces.html. Accessed January 20, 2015.
29. United States Department of Labor. Consumer Price Index [internet]. Washington, DC: Bureau of Labor Statistics. Available from http://www.bls.gov/cpi/. Accessed January 20, 2015.
30. Rognoni C, Marchetti M, Quaglini S, Liberato NL,. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis 2015; 39: 149-54.
31. Janzic A, Kos M,. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics 2015; 33: 395-408.
32. Wann LS, Curtis AB, Ellenbogen KA, et al., 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: 1144-50.
33. You JJ, Singer DE, Howard PA,. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-75S.
34. Limone BL, Baker WL, Kluger J, Coleman CI,. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One 2013; 8: e62183.
35. Dlott JS, George RA, Huang X, et al., National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014; 129: 1407-14.
36. Limone BL, Baker WL, Mearns ES, et al., Common flaws exist in published cost-effectiveness models on pharmacologic stroke prevention in atrial fibrillation. J Clin Epidemiol 2014; 67: 1093-102.